Paper Details

  1. Home
  2. Paper Details

Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis.

Author: Barrientos-GutiérrezTonatiuh, Chávez-TapiaNorberto C, Manzano-RobledaMaría Del Carmen, Méndez-SánchezNahum, Ornelas-ArroyoVictoria, UribeMisael

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Overview

This article reviews the benefits and harms of boceprevir and telaprevir in the treatment of genotype 1 hepatitis C virus infection. The study found that the addition of protease inhibitors to pegylated interferon and ribavirin resulted in a higher sustained viral response rate. The study also identified predictors of sustained viral response, such as IL-28 TT genotype, nonblack race, low viral load, age, no cirrhosis, statin use, undetectable viral load at the first anemia episode and at week 2 of treatment, and low IL-6 levels.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Treatment of hepatitis C virus (HCV) infection with newer direct-acting antivirals is unrealistic in some countries because of the lack of availability. AIM: Assess benefits and harms of boceprevir (BOC) and telaprevir (TLV) in treatment of genotype 1 HCV infection, and identifying subg...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/25536641

データ提供：米国国立医学図書館（NLM）

A New Dawn in Hepatitis C Treatment: Boceprevir and Telaprevir for Genotype 1 Infection

This research delves into the world of hepatitis C virus (HCV) treatment, focusing on the effectiveness of two protease inhibitors, boceprevir (BOC) and telaprevir (TLV), in patients with genotype 1 HCV infection. The authors conducted a comprehensive systematic review and meta-analysis of published and unpublished randomized trials, comparing the outcomes of treatment with BOC or TLV in combination with pegylated interferon and ribavirin (PR) to PR alone. They found that the combination therapy significantly increased sustained viral response (SVR) rates, particularly in patients who had previously been treated with PR. The study also identified several predictors of SVR, providing valuable insights into patient selection and optimizing treatment strategies. This research offers a valuable resource for healthcare professionals seeking to improve HCV treatment outcomes.

A Turning Point: The Impact of Protease Inhibitors on HCV Treatment

The study's findings reveal the significant impact of protease inhibitors, such as BOC and TLV, on HCV treatment outcomes. The researchers observed a substantial increase in SVR rates when these inhibitors were combined with PR, particularly in patients who had previously been treated with PR alone. It's like finding a new spring of vitality in the desert of HCV treatment, offering hope for improved outcomes and a better quality of life for individuals with this chronic infection. The study's results encourage the use of protease inhibitors in combination with PR for genotype 1 HCV infection, particularly in patients with previous treatment experience.

Moving Forward: Optimizing HCV Treatment Strategies

This research highlights the importance of personalized medicine and individualized treatment strategies for HCV infection. The study's findings underscore the need for careful patient selection, taking into account factors such as previous treatment experience and other individual characteristics. It's like navigating a complex desert, understanding the unique challenges of each path and choosing the most appropriate route to success. By embracing these personalized approaches, healthcare professionals can maximize the effectiveness of HCV treatment and improve patient outcomes.

Dr.Camel's Conclusion

This research offers a comprehensive overview of the effectiveness of boceprevir and telaprevir in combination with pegylated interferon and ribavirin for the treatment of genotype 1 HCV infection. The study's findings provide valuable insights into patient selection, treatment strategies, and the potential for improved patient outcomes. It's a reminder that persistent exploration and scientific advancement can lead to new breakthroughs in combating chronic diseases.

Date :
  1. Date Completed 2015-08-24
  2. Date Revised 2019-09-19
Further Info :

Pubmed ID

25536641

DOI: Digital Object Identifier

S1665-2681(19)30800-2

Related Literature

Article Analysis
・Effective treatment of hepatitis c
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.